| Orginal Article |
|
|
|
|
| The Research Status and Development Trend of Global Human Coronavirus Antibody Field |
LI Dong-qiao,LV Lu-cheng,YANG Yan-ping( ) |
| National Science Library, Chinese Academy of Sciences, Beijing 100190, China |
|
|
|
Abstract Antibodies play an important role in the diagnosis, treatment and prevention of diseases. With the continuous spread of pneumonia caused by the infection of Severe Acute Respiratory Syndrome Coronavirus 2(SARS-CoV-2), it is urgent to research antibodies against the virus. The patent information was downloaded from the IncoPat database and the drug information was downloaded from the Cortellis database. Through the combination of quantitative analysis and qualitative research, the patent situation analysis in the field of human coronavirus could be obtained from various dimensions, including application trends, technology distribution, country or region distribution, organization distribution and market status. The results showed that the United States was the country with the largest amount of patent technology, and China was the main country of patent protection. Three Chinese organizations, including the Chinese Academy of Sciences, entered the list of the global top ten organizations. The research on human coronavirus antibody products was mainly focused on SARS and MERS. In addition, some MERS antibodies entered the clinical stage. The results provide data reference and decision support for the research and development of Corona Virus Disease 2019(COVID-19).
|
|
Received: 11 February 2020
Published: 27 March 2020
|
|
|
|
Corresponding Authors:
Yan-ping YANG
E-mail: yangyp@mail.las.ac.cn
|
|
|
| [1] |
李东巧, 陈芳, Cynthia Liu , 等. 全球抗体药物研发态势分析. 中国生物工程杂志, 2019,39(5):11-21.
|
|
|
| [1] |
Li D Q, Chen F, Liu C , et al. Analysis of global antibody drug development trends. China Biotechnology, 2019,39(5):11-21.
|
|
|
| [2] |
Sui J H, Li W H, Murakami A , et al. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. PNAS, 2004,101(8):2536-2541.
|
|
|
| [3] |
Cleri D J, Ricketti A J, Vernaleo J R . Severe acute respiratory syndrome (SARS). Infectious Disease Clinics of North America, 2010,24(1):175.
|
|
|
| [4] |
Zhu Z Y, Chakraborti S, He Y , et al. Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. PNAS, 2007,104(29):12123-12128.
|
|
|
| [5] |
Ohnuma K, Haagmans B L, Hatano R , et al. Inhibition of Middle East Respiratory Syndrome coronavirus infection by anti-CD26 monoclonal antibody. Journal of Virology, 2013,87(24):13892-13899.
|
|
|
| [6] |
Ying T L, Du L Y, Ju T W , et al. Exceptionally potent neutralization of Middle East Respiratory Syndrome coronavirus by human monoclonal antibodies. Journal of Virology, 2014,88(14):7796-7805.
|
|
|
| [7] |
Qiu T Y, Mao T T, Wang Y , et al. Identification of potential cross-protective epitope between 2019-nCoV and SARS virus. Journal of Genetics and Genomics, 2020, In Press Journal Pre-proof.
|
|
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
